← Back to headlines
PharmX Highlights 73% Marketplace Surge Amid Cost Pressures in FY26 Results
PharmX presented its FY26 financial slides showing a substantial 73 percent increase in marketplace activity, though elevated investment costs continue to weigh on overall EBITDA performance.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
